2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Metabolic Enzyme/Protease
  4. HSP

HSP

Heat shock proteins

HSP

Related Products

PDF 1.64 MB

HSP (Heat shock proteins) are a group of proteins induced by heat shock, the most prominent members of this group are a class of functionally related proteins involved in the folding and unfolding of other proteins. HSP expression is increased when cells are exposed to elevated temperatures or other stress. This increase in expression is transcriptionally regulated. The dramatic upregulation of the heat shock proteins is a key part of the heat shock response and is induced primarily by heat shock factor (HSF). HSPs are found in virtually all living organisms, from bacteria to humans. Heat shock proteins appear to serve a significant cardiovascular role. Hsp90, Hsp84, Hsp70, Hsp27, Hsp20 and alpha B crystallin all have been reported as having roles in the cardiovasculature.

HSP Isoform Specific Products:

HSP Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-RS06407
    Hsf1 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Hsf1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Hsf1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Hsf1 Mouse Pre-designed siRNA Set A
    Hsf1 Mouse Pre-designed siRNA Set A
  • HY-N0830S8
    Palmitic acid-9,10-d2
    		Activator
    Palmitic acid-9,10-d2 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants. Palmitic acid can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells.
    Palmitic acid-9,10-d<sub>2</sub>
  • HY-149780
    Flavokawain 1i
    		Inhibitor
    Flavokawain 1i (DiNap) is an Hsp90 inhibitor. Flavokawain 1i (DiNap) has anti-cell proliferation activity and can be used in cancer research.
    Flavokawain 1i
  • HY-N15154
    Tasiamide B
    		Inhibitor
    Tasiamide B is a Cathepsin D inhibitor, which is a linear peptide found in the marine cyanobacteria Symploca sp.. Tasiamide B is proved as a good template for the development of aspartic proteases inhibitors. Tasiamide B is effective against skin cancer by strongly interacting with the target protein HSP90.
    Tasiamide B
  • HY-136312
    17-DMAP-GA
    17-DMAP-GA, a Geldanamycin (HY-15230) analogue, is an inhibitor of HSP90. 17-DMAP-GA causes cell cycle abnormalities.
    17-DMAP-GA
  • HY-125974A
    HM03 trihydrochloride
    		Inhibitor
    HM03 trihydrochloride is a potent and selective HSPA5 (Heat shock 70kDa protein 5, also known as Bip, Grp78) inhibitor. HM03 trihydrochloride has anticancer activity.
    HM03 trihydrochloride
  • HY-162900
    HSP90-IN-32
    		Inhibitor
    HSP90-IN-32 is a Hsp90 C-terminal inhibitor that displays anti-proliferative activities against SKMel173, SKMel103, SKMel19 and A375 cells with IC50 values of 1.01 μM, 0.782 μM, 0.607 μM and 1.413 μM , respectively. HSP90-IN-32 is promising for research of anti-cancer agents.
    HSP90-IN-32
  • HY-149531
    HSP90-IN-25
    		Inhibitor
    HSP90-IN-25 (compound 4a) is an HSP90 inhibitor that specifically inhibits the ATPase activity of HSP90.
    HSP90-IN-25
  • HY-RS06406
    HSF1 Human Pre-designed siRNA Set A
    		Inhibitor

    HSF1 Human Pre-designed siRNA Set A contains three designed siRNAs for HSF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    HSF1 Human Pre-designed siRNA Set A
    HSF1 Human Pre-designed siRNA Set A
  • HY-151335
    KU-177
    		Inhibitor
    KU-177 is a potent inhibitor of Hsp90 ATPase homologue 1 (Aha1), ablates Aha1-driven enhancement of Hsp90-dependent tau aggregation. KU-177 also disrupts Aha1/Hsp90 interactions (IC50=4.08 μM) without inhibition of Hsp90’s ATPase activity. KU-177 can be used for tauopathies research.
    KU-177
  • HY-148745
    JG-258
    		Inhibitor
    JG-258 is an inactive negative control for Hsp70 inhibitors.
    JG-258
  • HY-170910
    Hsp90-IN-39
    		Inhibitor
    Hsp90-IN-39 (Compound 16t) is a HSP90 inhibitor with notable selectivity for the HSP90α isoform. Hsp90-IN-39 demonstrates significant antiproliferative activity in various cancer cell lines, including MCF-7, HCT116, SKBr3, K562, and A549. Hsp90-IN-39 holds potential for cancer research.
    Hsp90-IN-39
  • HY-145814
    HSP90-IN-9
    		Inhibitor
    HSP90-IN-9 is a potent and selective HSP90 inhibitor. HSP90-IN-9 displays a fungicidal effect in a dose-dependent manner. HSP90-IN-9 inhibits fungal biofilm formation and fungal morphological changes after being combined with FLC. HSP90-IN-9 recovers FLC resistance by down-regulating the expression of related genes (ERG11, CDR1 and CDR2).
    HSP90-IN-9
  • HY-168178
    Hsp110-STAT3 interaction-IN-2
    		Inhibitor
    Hsp110-STAT3 interaction-IN-2 (compound 10b) is a Hsp110-STAT3 interaction disruptor. Hsp110-STAT3 interaction-IN-2 can be used in pulmonary arterial hypertension (PAH) related research.
    Hsp110-STAT3 interaction-IN-2
  • HY-161826
    Antitumor agent-174
    Antitumor agent-174 (Compound 10) directly engages the N-terminal site of Hsp90 and promotes the degradation of β-catenin, thereby suppressing the Wnt/β-catenin signaling. Antitumor agent-174 effectively inhibits proliferation, induce S and G2/M phases arrest and block the clonogenic ability in CRC cells. Antitumor agent-174 down-regulates CDK1, Cyclin D1, c-Myc, Cyclin B1, and Cyclin A2, and upregulaties P21 proteins. Antitumor agent-174 has significant anti-tumor efficacy against colorectal cancer (CRC) with excellent pharmacokinetics and low toxicity.
    Antitumor agent-174
  • HY-10389A
    Alvespimycin TFA
    		Inhibitor 98.97%
    Alvespimycin (17-DMAG) TFA is a potent inhibitor of Hsp90, binding to Hsp90 with an EC50 of 62 ± 29 nM.
    Alvespimycin TFA
  • HY-155580
    MAO A/HSP90-IN-2
    		Inhibitor
    MAO A/HSP90-IN-2 (compound 4-C) is a dual inhibitor of HSP90and MAO A with the IC50 values of 0.016 and 4.58 μM, respectively. MAO A/HSP90-IN-2 increases HSP70 expression and reduces HER2 and phospho-Akt expression, and decreases IFN-γ induced PD-L1 expression in GL26 cells. MAO A/HSP90-IN-2 inhibits the growth of Temozolomide (HY-17364) -sensitive and -resistant GBM cells, colon cancer, leukemia, non-small cell lung and other cancers, and has potential to inhibit tumor immune escape[1].
    MAO A/HSP90-IN-2
  • HY-155064
    TRAP1-IN-2
    		Inhibitor
    TRAP1-IN-2 (compound 36) is a selective degrader of TRAP1 downstream proteins without affecting Hsp90's cytoplasmic downstream proteins. TRAP1-IN-2 also inhibits OXPHOS and alters cellular glycolysis metabolism. TRAP1-IN-2 destabilizes TRAP1 tetramers and disrupts mitochondrial membrane potential.
    TRAP1-IN-2
  • HY-108248
    KU-32
    		Inhibitor
    KU-32 is a novel, novobiocin-based Hsp90 inhibitor that can protect against neuronal cell death.
    KU-32
  • HY-10211S
    Tanespimycin-d5
    Tanespimycin-d5 (17-AAG-d5; NSC 330507-d5; CP 127374-d5) is the deuterium labeled Tanespimycin (HY-10211). Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90. Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression.
    Tanespimycin-d<sub>5</sub>
Cat. No. Product Name / Synonyms Application Reactivity
HSP Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.